



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,280	10/622,280 07/18/2003		Rajeev S. Bhide	LD0339 NP 4608	
23914	7590	EXAM	INER		
STEPHEN BRISTOL		IS QUIBB COMPA	BALASUBRAMANIAN, VENKATARAMAN		
PATENT I		•	ART UNIT	PAPER NUMBER	
P O BOX 4	000		1624		
PRINCETO	ON, NJ 08	3543-4000	DATE MAILED: 08/03/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/622,280	BHIDE ET AL.				
Office Action Summary	Examiner	Art Unit				
	Venkataraman Balasubramanian	1624				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time y within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
2a) This action is FINAL . 2b) ⊠ This	action is non-final.					
3) Since this application is in condition for allowar	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-16 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-16 are subject to restriction and/or election requirement.						
Application Papers						
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)	. П					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (Paper No(s)/Mail Dat	PTO-413) de				
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal Pa					

Application/Control Number: 10/622,280

Art Unit: 1624

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, drawn to a process of making compound of formula I, classified in class 544, subclass 183 and other classes and subclasses depending upon the choice of heterocyclic or heteroaryl groups.
- II. Claim11, drawn to a pharmaceutical composition of the compound of formula I and other anticancer or cytotoxic agents, classified in class 514, subclass 243 and other classes and subclasses depending upon the choice of heterocyclic or heteroaryl groups, as well as choice of the anticancer or cytotoxic agents for combination.
- III. Claims 12-16, drawn to several method of use of the compound of formulaI, classified in class 514, subclass 24, and other subclasses dependingupon the choice of heterocyclic or heteroaryl groups.

The inventions are distinct, each from the other because of the following reasons:

As per MPEP § 803, there are two criteria for a proper requirement for restriction between patentably distinct inventions:

- (A) The inventions must be independent or distinct as claimed and
- (B) There must be a serious burden on the examiner if restriction is required.

Invention I, II and III are independent and distinct from each other because they are directed to functionally different / dissimilar inventions. Group I relates to a process

of making a compound of formula I while Group II is combination pharmaceutical composition and Group III relates various method of use of compound of formula I. It should be clear that Group II and Group III dependent on process claim (which is improper) not a compound claim. Consequently, the groups have different classifications and require separate prior art searches. They can be made and used independently. Art which may render obvious or anticipate one of the groups would not necessarily do the same for the other group. Some references cited in the Information Disclosure Statement may anticipate one of the group but may not do the same for other groups embraced. Likewise a process for making the said compound even if it is known, it would not be relevant to the method of use claims. Each can support a patent, as the each group are capable of being utilized alone not in combination with other group.

In addition, it is necessary to classify and search all the controlling hetero cores and such a search of all controlling heterocores would serious search burden given the limited time available for each application.

In view of distinct nature of each of the invention, the restriction is set forth in writing.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

Page 4

Application/Control Number: 10/622,280

Art Unit: 1624

or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by

a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication from the examiner should be

addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571)

272-0662. The examiner can normally be reached on Monday through Thursday from

8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is

Mukund Shah whose telephone number is (571) 272-0674. If Applicants are unable to

reach Mukund Shah within 24-hour period, they may contact James O. Wilson, Acting-

SPE of art unit 1624 at 571-272-0661. The fax phone number for the organization

where this application or proceeding is assigned (703) 872-9306. Any inquiry of a

general nature or relating to the status of this application or proceeding should be

directed to the receptionist whose telephone number is (571) 272-1600.

Veukataraman Balasuhramanian Venkataraman Balasuhramanian

7/28/2004